Hare
HomeInsights

INDUSTRY:

Pharma

TOPIC:

Products & Services

TITLE:

NMMDA: Direct communication to healthcare professionals with regrad to tyrosine kinase inhibitors BCR-ABL (imatinib, dasatinib, nilotinib, dasatinib, ponatinib)

BRIEF:

A direct communication to Healthcare Professionals regarding the need to conduct a preliminary test before starting the treatment with tyrosine kinase inhibitors BCR-ABL was recently posted on the official website of the National Medicine and Medical Devices Agency.

LEGAL IMPLICATIONS:

BUSINESS IMPLICATIONS:

Special Report

In an unexpected move, just before the end of 2011, ...

Case Study

Improving expenditure efficiency has been, for a ver...

Your Portal Link to Mass Media Universe.

Valuable Quarterly Romanian Market Analysis.

Ask the analyst

Tailor-made advice for you

Feature Company